Jeffrey M McManus1, Navin Sabharwal1, Peter Bazeley2, Nima Sharifi1,3,4. 1. Genitourinary Malignancies Research Center, Lerner Research Institute. 2. Center for Clinical Genomics, Genomics Medicine Institute. 3. Department of Hematology and Oncology, Taussig Cancer Institute. 4. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
Context: A sex discordance in COVID exists, with males disproportionately affected. Although sex steroids may play a role in this discordance, no definitive genetic data exist to support androgen-mediated immune suppression neither for viral susceptibility nor for adrenally produced androgens. Objective: The common adrenal-permissive missense-encoding variant HSD3B1(1245C) that enables androgen synthesis from adrenal precursors and that has been linked to suppression of inflammation in severe asthma was investigated in COVID susceptibility and outcomes reported in the UK Biobank. Methods: The UK Biobank is a long-term study with detailed medical information and health outcomes for over 500 000 genotyped individuals. We obtained COVID test results, inpatient hospital records, and death records and tested for associations between COVID susceptibility or outcomes and HSD3B1(1245A/C) genotype. Primary analyses were performed on the UK Biobank Caucasian cohort. The outcomes were identification as a COVID case among all subjects, COVID positivity among COVID-tested subjects, and mortality among subjects identified as COVID cases. Results: Adrenal-permissive HSD3B1(1245C) genotype was associated with identification as a COVID case (odds ratio (OR): 1.11 per C allele, 95% CI: 1.04-1.18, P = 0.0013) and COVID-test positivity (OR: 1.09, 95% CI: 1.02-1.17, P = 0.011) in older (≥70 years of age) women. In women identified as COVID cases, there was a positive linear relationship between age and 1245C allele frequency (P < 0.0001). No associations were found between genotype and mortality or between genotype and circulating sex hormone levels. Conclusion: Our study suggests that a common androgen synthesis variant regulates immune susceptibility to COVID infection in women, with increasingly strong effects as women age.
Context: A sex discordance in COVID exists, with males disproportionately affected. Although sex steroids may play a role in this discordance, no definitive genetic data exist to support androgen-mediated immune suppression neither for viral susceptibility nor for adrenally produced androgens. Objective: The common adrenal-permissive missense-encoding variant HSD3B1(1245C) that enables androgen synthesis from adrenal precursors and that has been linked to suppression of inflammation in severe asthma was investigated in COVID susceptibility and outcomes reported in the UK Biobank. Methods: The UK Biobank is a long-term study with detailed medical information and health outcomes for over 500 000 genotyped individuals. We obtained COVID test results, inpatient hospital records, and death records and tested for associations between COVID susceptibility or outcomes and HSD3B1(1245A/C) genotype. Primary analyses were performed on the UK Biobank Caucasian cohort. The outcomes were identification as a COVID case among all subjects, COVID positivity among COVID-tested subjects, and mortality among subjects identified as COVID cases. Results: Adrenal-permissive HSD3B1(1245C) genotype was associated with identification as a COVID case (odds ratio (OR): 1.11 per C allele, 95% CI: 1.04-1.18, P = 0.0013) and COVID-test positivity (OR: 1.09, 95% CI: 1.02-1.17, P = 0.011) in older (≥70 years of age) women. In women identified as COVID cases, there was a positive linear relationship between age and 1245C allele frequency (P < 0.0001). No associations were found between genotype and mortality or between genotype and circulating sex hormone levels. Conclusion: Our study suggests that a common androgen synthesis variant regulates immune susceptibility to COVID infection in women, with increasingly strong effects as women age.
Authors: Rudragouda Channappanavar; Craig Fett; Matthias Mack; Patrick P Ten Eyck; David K Meyerholz; Stanley Perlman Journal: J Immunol Date: 2017-04-03 Impact factor: 5.422
Authors: Hanieh Yaghootkar; Michael P Bancks; Sam E Jones; Aaron McDaid; Robin Beaumont; Louise Donnelly; Andrew R Wood; Archie Campbell; Jessica Tyrrell; Lynne J Hocking; Marcus A Tuke; Katherine S Ruth; Ewan R Pearson; Anna Murray; Rachel M Freathy; Patricia B Munroe; Caroline Hayward; Colin Palmer; Michael N Weedon; James S Pankow; Timothy M Frayling; Zoltán Kutalik Journal: Hum Mol Genet Date: 2017-03-01 Impact factor: 6.150
Authors: Graeme Eisenhofer; Mirko Peitzsch; Denise Kaden; Katharina Langton; Christina Pamporaki; Jimmy Masjkur; George Tsatsaronis; Anastasios Mangelis; Tracy A Williams; Martin Reincke; Jacques W M Lenders; Stefan R Bornstein Journal: Clin Chim Acta Date: 2017-05-04 Impact factor: 3.786
Authors: Jeffrey M McManus; Kelsey Bohn; Mohammad Alyamani; Yoon-Mi Chung; Eric A Klein; Nima Sharifi Journal: PLoS One Date: 2019-10-17 Impact factor: 3.240
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Megan L Kruse; Mona Patel; Jeffrey McManus; Yoon-Mi Chung; Xiuxiu Li; Wei Wei; Peter S Bazeley; Fumihiko Nakamura; Aimalie Hardaway; Erinn Downs; Sarat Chandarlapaty; Mathew Thomas; Halle Cf Moore; George T Budd; W H Wilson Tang; Stanley L Hazen; Aaron Bernstein; Serena Nik-Zainal; Jame Abraham; Nima Sharifi Journal: JCI Insight Date: 2021-10-22